LENZ Therapeutics (LENZ) Analyst & Key Data

Analyst Consensus

Buy4 analysts

Buy

Updated Sep 12, 2026

Total Analysts4

Buy

4

Hold

1

Ratings

Updated Sep 12, 2026

Overall Rating

B-

DCF Score3.0 / 5

Debt / Equity Score5.0 / 5

Price / Book Score4.0 / 5

Price / Earnings Score1.0 / 5

ROA Score1.0 / 5

ROE Score1.0 / 5

Valuation

Current Stock Price

$4.52

Median Target+685.40%

$35.50

Potential upside vs current price

DCF Value-47.34%

$2.38

Potential downside vs current price

Current Stock Price

$4.52

Median Target+685.40%

$35.50

Potential upside vs current price

DCF Value-47.34%

$2.38

Potential downside vs current price

Analyst Consensus

Buy4 analysts

Buy

Updated Sep 12, 2026

Total Analysts4

Buy

4

Hold

1

Ratings

Updated Sep 12, 2026

Overall Rating

B-

DCF Score3.0 / 5

Debt / Equity Score5.0 / 5

Price / Book Score4.0 / 5

Price / Earnings Score1.0 / 5

ROA Score1.0 / 5

ROE Score1.0 / 5

Valuation

Current Stock Price

$4.52

Median Target+685.40%

$35.50

Potential upside vs current price

DCF Value-47.34%

$2.38

Potential downside vs current price

Current Stock Price

$4.52

Median Target+685.40%

$35.50

Potential upside vs current price

DCF Value-47.34%

$2.38

Potential downside vs current price

LENZ Therapeutics, Inc.